ICU Medical (ICUI) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic positioning and risk-reward outlook

• Management sees improved risk-reward, citing operational improvements and closing the under-earning gap by 2025.

• Three drivers: operational fixes, sector-specific market share opportunities, and favorable macro trends like currency and logistics.

• Recent joint venture with Otsuka for IV solutions shifts focus to core infusion business and improves financial profile.

• Company now leans more international, with about one-third of revenue outside North America post-JV.

• Enterprise value is around $5 billion, with net debt expected to fall to $1 billion by year-end 2024.

Business segments and growth drivers

• Consumables are the largest and most profitable segment, compounding at 6–7% annually for several years.

• Pump business is positioned for growth with new products (Duo, Solo, Medfusion 5000) and a large installed base due for refresh.

• Vital Care segment, now smaller post-JV, remains a chronic care leader, especially in tracheostomy.

• Oncology and vascular access are key growth drivers, with oncology rebounding post-COVID and vascular access showing turnaround.

• 80% of revenue is from single-use disposables, with a strong recurring revenue profile.

Innovation, technology, and market opportunity

• Industry is highly consolidated with high regulatory barriers and sticky, recurring revenues.

• New product cycle underway, with focus on IT integration, EHR interoperability, and software monetization in infusion systems.

• Bidirectional connectivity and cloud-based systems are differentiators, enabling better safety, workflow, and home care integration.

• Market share shifts in the U.S. pump market present significant NPV opportunities as hospitals are forced to evaluate new platforms.

• Company is the "focus player" in its markets, emphasizing customer service, vertical integration, and cost leadership.